The ITN conducts clinical trials with the goal of achieving immune tolerance for patients. To see a list of ITN's clinical trials that are currently enrolling participants, please select a disease area:
Below is a list of online resources that will help you decide whether participation in a clinical trial is the right decision for you.
To see all of ITN's active and completed studies, please visit For Researchers.
(
ITN093AI
|
DARE-APS
)
Principal Investigator:
Doruk Erkan | Hospital for Special Surgery | New York, NY
Jason Knight | University of Michigan | Ann Arbor, MI
A study about the safety of daratumumab in patients with antiphospholipid syndrome (APS), and its effectiveness at reducing the antiphospholipid antibodies that cause APS.
Category:
Autoimmune Disease
|
Specific Category:
Primary Antiphospholipid Syndrome
|
Status:
Enrollment
Learn more:
(
ITN091AI
|
VIBRANT
)
Principal Investigator:
Maria Dall'era | University of California San Francisco | San Francisco, CA
Betty Diamond | The Feinstein Institute for Medical Research | Manhasset, NY
David Wofsy | University of California San Francisco | San Francisco, CA
The goal of the VIBRANT trial is to determine if treating lupus nephritis with VIB4920 in addition to standard therapy is more effective than treating lupus nephritis with standard therapy alone.
Category:
Autoimmune Disease
|
Specific Category:
Lupus Nephritis
|
Status:
Enrollment
Learn more:
(
ITN090ST
|
ATTAIN
)
Principal Investigator:
Flavio Vincenti | University of California San Francisco | San Francisco, CA
Rajalingam Raja | University of California San Francisco | San Francisco, CA
The goal of ATTAIN is to study whether using two drugs, daratumumab and belatacept, together can lower the number of plasma cells in “highly sensitized” people on the kidney transplant waiting list.
Category:
Transplantation
|
Specific Category:
Kidney Transplantation
|
Status:
Enrollment
Learn more:
(
ITN089ST
|
ADAPT
)
Principal Investigator:
Stuart Knechtle | Duke University School of Medicine | Durham, NC
The goal of the ADAPT study is to study whether using two drugs, carfilzomib and belatacept, together can lower the number of plasma cells in “highly sensitized” people on the kidney transplant waiting list.
Category:
Transplantation
|
Specific Category:
Kidney Transplantation
|
Status:
Enrollment
Learn more:
(
ITN080AI
|
REBOOT
)
Principal Investigator:
Patrick Nachman | University of Minnesota | Minneapolis, MN
REBOOT will test whether a combination of, belimumab and rituximab, is safe and if this combination is more effective at blocking the immune attack on the kidney of patients with Primary Membranous Neuropathy (MN).
Category:
Autoimmune Disease
|
Specific Category:
Autoimmune Diseases
|
Status:
Enrollment
Learn more:
Principal Investigator:
Jeffrey Cohen | Cleveland Clinic | Cleveland, OH
Paolo Muraro | Imperial College London | London, England
George Georges | Fred Hutchinson Cancer Research Center | Chicago, IL
BEAT-MS is a clinical trial comparing chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT) – a type of bone marrow transplantation – to the most effective medicines regularly used to treat relapsing MS.
Category:
Autoimmune Disease
|
Specific Category:
Multiple Sclerosis
|
Status:
Enrollment
Learn more:
